Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis

Perry Shen, Edward A. Levine, Jason Hall, Doug Case, Greg Russell, Ronald Fleming, Richard McQuellon, Kim R. Geisinger, Brian W. Loggie

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P

Original languageEnglish
Pages (from-to)26-33
Number of pages8
JournalArchives of Surgery
Volume138
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Mitomycin
Carcinoma
Drug Therapy
Survival
Peritoneal Cavity
Survival Analysis
Multivariate Analysis
Survival Rate
Perfusion
Outcome Assessment (Health Care)
Clinical Trials
Neoplasm Metastasis
Temperature
Liver
Population

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. / Shen, Perry; Levine, Edward A.; Hall, Jason; Case, Doug; Russell, Greg; Fleming, Ronald; McQuellon, Richard; Geisinger, Kim R.; Loggie, Brian W.

In: Archives of Surgery, Vol. 138, No. 1, 01.01.2003, p. 26-33.

Research output: Contribution to journalArticle

Shen, Perry ; Levine, Edward A. ; Hall, Jason ; Case, Doug ; Russell, Greg ; Fleming, Ronald ; McQuellon, Richard ; Geisinger, Kim R. ; Loggie, Brian W. / Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. In: Archives of Surgery. 2003 ; Vol. 138, No. 1. pp. 26-33.
@article{32c21fd0031b45b9aa6babdc6cca609a,
title = "Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis",
abstract = "Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61{\%} and 33{\%}, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P",
author = "Perry Shen and Levine, {Edward A.} and Jason Hall and Doug Case and Greg Russell and Ronald Fleming and Richard McQuellon and Geisinger, {Kim R.} and Loggie, {Brian W.}",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "138",
pages = "26--33",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis

AU - Shen, Perry

AU - Levine, Edward A.

AU - Hall, Jason

AU - Case, Doug

AU - Russell, Greg

AU - Fleming, Ronald

AU - McQuellon, Richard

AU - Geisinger, Kim R.

AU - Loggie, Brian W.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P

AB - Hypothesis: Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Design: Prospective clinical trial. Setting: Surgical oncology service at a university academic hospital. Patients: A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. Intervention: All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C. Main Outcome Measures: Clinicopathologic factors that independently predicted improved overall survival rates. Results: Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P=.001), the appendix as a primary site (P=.003), the absence of hepatic parenchymal metastases (P=.01), and complete resection of all gross disease (R1/0 resection) (P

UR - http://www.scopus.com/inward/record.url?scp=0037228382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037228382&partnerID=8YFLogxK

M3 - Article

VL - 138

SP - 26

EP - 33

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 1

ER -